Diazepam (Valtoco) vs Stiripentol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Diazepam (Valtoco)

Marketed by Neurelis, Inc.

Approved in Epilepsysmall molecule
Weak signal

NCT02721069 · Phase 3 · completed

The study was open-label, nonrandomized, and had no placebo or active comparator, so it provides uncontrolled safety and treatment-exposure information rather than comparative evidence of effectiveness. Its primary endpoint was the number of participants receiving NRL-1 over 12 months, not a hard clinical seizure outcome, and no formal primary-endpoint comparison was applicable.

Next expected readout: December 2026 · NCT06346262 (registry estimate)

Reported efficacy

Number of Participants Who Received NRL-1 (Valtoco) (12 months): Number of Participants Who Received NRL-1 (Valtoco) (12 months): NRL-1 5mg 9 Participants | NRL-1 10mg 54 Participants | NRL-1 15 mg 46 Participants | NRL-1 20mg 54 Participants (not_applicable)

Result source: NCT02721069

Stiripentol

Marketed by Biocodex

Approved in Epilepsysmall molecule
Weak signal

NCT07176832 · Phase 1 · completed

This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDiazepam (Valtoco)Stiripentol
Seizure frequency, % change—Not reported—Not reported
50% responder rate—Not reported—Not reported
Seizure freedom—Not reported—Not reported

Seizure frequency, % change

Diazepam (Valtoco)
—Not reported
Stiripentol
—Not reported

50% responder rate

Diazepam (Valtoco)
—Not reported
Stiripentol
—Not reported

Seizure freedom

Diazepam (Valtoco)
—Not reported
Stiripentol
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Stiripentol: no structured comparison results are available for Epilepsy.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Diazepam (Valtoco): 3 of 4 rows · Stiripentol: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDiazepam (Valtoco)
Dropout rate
—20mga
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
—15mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—10mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—5mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
5.3%
NCT02724423 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—20mga
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
—15mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—10mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—5mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—
NCT02724423 · Phase 1 · registry result, not featured evidence
Serious AEs
24.1%20mga
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
32.6%15mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
37%10mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
22.2%5mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
1.8%
NCT02724423 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
20mga
nasal discomfort 11.1%
nasopharyngitis 7.4%
upper respiratory tract infection 7.4%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
15mg
seizure 15.2%
upper respiratory tract infection 15.2%
nasal discomfort 8.7%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
10mg
nasopharyngitis 22.2%
pyrexia 18.5%
upper respiratory tract infection 16.7%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
5mg
influenza 33.3%
diarrhoea 22.2%
nasopharyngitis 11.1%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
dysgeusia 5.3%
nasal discomfort 3.5%
nasopharyngitis 3.5%
NCT02724423 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Valtoco)'s landscape · Stiripentol's landscape